United Therapeutics Corporation Reports First Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
United Therapeutics Corp. (UTHR) PT Raised to $250 at Cowen
May 4, 2022 3:47 PM EDTCowen analyst Joseph Thome raised the price target on United Therapeutics Corp. (NASDAQ: UTHR) to $250.00 (from $240.00) while maintaining an Outperform rating following earnings.
The analyst commented, "UTHR reported strong revenues across the franchise to beat consensus expectations for the quarter. A positive... More
United Therapeutics (UTHR) Tops Q1 EPS by $1.69
May 4, 2022 6:10 AM EDTUnited Therapeutics (NASDAQ: UTHR) reported Q1 EPS of $5.03, $1.69 better than the analyst estimate of $3.34. Revenue for the quarter came in at $461.9 million versus the consensus estimate of $420.02 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
... More